Sirnaomics Receives FDA Feedback on STP705 Development Plan for isSCC Treatment
Sirnaomics Ltd (HKG: 2257), a leading biopharmaceutical company focused on the discovery and development of...
Clinical trial approval / initiation
Sanofi Advances Phase I/II Trial of Trifunctional NK Cell Engager in Blood Cancers
Sanofi (NASDAQ: SNY), a French multinational pharmaceutical company, has administered the first dose to a...
Keymed Biosciences Achieves First Dosing in Global Phase III Trial for Claudin 18.2 Targeting ADC
Keymed Biosciences Inc., (HKG: 2162), a biopharmaceutical company based in China, has announced the completion...
Hengrui Pharmaceuticals Gets NMPA Approval for Clinical Study of CDK 4/6 Inhibitor Combo in Breast Cancer
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a prominent pharmaceutical company in China, has announced...
Laekna’s Anti-ActRIIA Antibody LAE102 Clears FDA Hurdle for Obesity Treatment Trial
Sino-American biotech firm Laekna has announced that it has received clinical trial approval from the...
Suzhou Zelgen Receives NMPA Approval for Jacktinib Cream Trial in Vitiligo Patients
Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) has announced that it has received approval from...
Haisco Pharmaceutical Gets NMPA Green Light for HSK31858 COPD Trial
Haisco Pharmaceutical Group Co., Ltd (SHE: 002653), a Chinese pharmaceutical company, has announced that it...
Yantai Dongcheng Secures Approval for Phase I Study of 68Ga-LNC1007 in Singapor
Yantai Dongcheng Pharmaceutical Group Co., Ltd. (SHE: 002675) has received approval from the Health Sciences...
Jiangsu Hengrui Secures NMPA Approval for Clinical Study of SHR-A2102 and SHR-8068 in Advanced Tumors
Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) has received approval from the National Medical Products...
Sichuan Biokin Pharmaceuticals Initiates Phase III Trial for BL-M05D1 in Esophageal Cancer
Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506) has announced the commencement of patient enrollment in...
Jiangsu Hengrui Pharmaceuticals Advances Pipeline with NMPA Approvals for Three Drugs
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) has received clinical trial approvals from China’s National...
Jiangsu Hengrui Pharmaceuticals Gains NMPA Approval for HRS-4642 Clinical Trial in KRAS G12D Mutated Tumors
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) has received approval from the National Medical Products...
Gan & Lee Pharmaceuticals Commences Clinical Trial for Innovative GLP-1 Agonist GZR18
Gan & Lee Pharmaceuticals (SHA: 603087), a leading Chinese pharmaceutical company, has announced the commencement...
Jiangsu Hengrui Pharmaceuticals Secures IND Approvals for Two Drug Candidates from China’s NMPA
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) has received Investigational New Drug (IND) approvals from...
Abbisko Therapeutics Achieves Milestone in Global Phase III Trial for Pimicotinib in Tendon Sheath Giant Cell Tumor
Shanghai-based biotech firm Abbisko Therapeutics Co., Ltd (HKG: 2256) has announced the completion of subject...
Huadong Medicine Gets NMPA Approval for Clinical Trial of FRα-Targeting ADC Elahere
China-based Huadong Medicine Co., Ltd (SHE: 000963) has announced that it has received approval from...
Hinova Pharmaceuticals Receives NMPA Greenlight for HP501 Clinical Trial in Gout Patients
Shanghai-based Hinova Pharmaceuticals Inc. (SHA: 688302) has announced that it has received approval from the...
IASO Biotherapeutics Gains FDA Nod for Fucaso CAR-T Study in Myasthenia Gravis
China-based IASO Biotherapeutics has received approval from the U.S. Food and Drug Administration (FDA) to...
Sichuan Biokin Secures NMPA Approval for Phase II Study of BL-M07D1 in Advanced Solid Tumors
Sichuan Biokin Pharmaceutical Co., Ltd. (SHA: 688506), based in China, has announced that it has...
Shanghai Fosun Pharma and Meiji Seika Pharma Launch Phase III Studies for Anti-Infective Nacubactam
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196), a leading pharmaceutical company based...